Reuters报道，9 月 21 日——Moderna 首席医疗官保罗.伯顿表示，该公司非常“渴望”与中国合作，向该国供应其基于 mRNA 的新冠疫苗。

TOKYO, Sept 21 (Reuters) - Moderna Inc (MRNA.O) Chief Medical Officer Paul Burton said on Wednesday the company is "eager" to collaborate with China on supplying its mRNA-based COVID-19 vaccines to the country.

上周，Moderna 首席执行官 Stephane Bancel 在东京表示，该公司已与中国就供应疫苗进行了会谈，但尚未做出任何决定。详情

The comments follow those of Moderna chief executive Stephane Bancel, who last week in Tokyo said the company has held talks with the Chinese government about supplying vaccines but no decision has yet been made

“如果中国认为需要疫苗，我们当然会非常渴望与中国合作，”伯顿在亚洲向记者举行的媒体简报会上说。“目前，没有开展任何活动，但我们对此持非常开放的态度。”

"We would certainly be very eager to collaborate with China if they felt that there was a need for a vaccine there," Burton told a media briefing to reporters in Asia. "Currently, there is no activity going on, but we'd be very open to it."

说到mRNA疫苗，不得不提复必泰新冠疫苗，复星医药2020年3月就与德国BioNTech展开技术合作。截至今日已向港澳台地区供应超过3000万剂量复必泰疫苗，针对奥密克戎变研发的二价疫苗也已上市，但内地至今仍未上市，已成疫情以来的最大谜团。